知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.025 seconds)

    Imaging tissue sites of inflammation
    2.
    发明授权
    Imaging tissue sites of inflammation 失效
    成像组织部位炎症

    公开(公告)号：US5376356A

    公开(公告)日：1994-12-27

    申请号：US726894

    申请日：1991-07-08

    Applicant: A. Charles Morgan, Jr.

    Inventor： A. Charles Morgan, Jr.

    IPC: A61K49/00 ,  A61K51/04 ,  A61K51/10 ,  A61K51/12 ,  A61K49/02

    CPC classification number: A61K51/1203 ,  A61K49/0004 ,  A61K51/04 ,  A61K51/1093 ,  A61K2123/00

    Abstract: The present invention involves a method of imaging tissue sites of inflammation which takes advantage of the up-regulation of surface antigenic markers on leukocytes upon activation thereof. A recognition agent selected from the group of chemotactic peptides, eosinophilic peptides and agents which are capable of selective interaction with a chemotactic receptor associated with activated leukocytes is radiolabeled. The radiolabeled recognition agent is infused into a patient and the patient's tissue sites are thereafter imaged in order to detect, evaluate or monitor tissue damage mediated by inflammation.

    Abstract translation: 本发明涉及一种成像炎症组织部位的方法，该方法在活化时利用白细胞上表面抗原标志物的上调。 可以放射性标记选自趋化性肽，嗜酸性肽和能够与与活化的白细胞相关的趋化性受体选择性相互作用的试剂组的识别剂。 将放射性标记的识别剂输注入患者，然后将患者的组织部位成像，以便检测，评估或监测炎症介导的组织损伤。

    Biotinylated cobalamins
    3.
    发明授权
    Biotinylated cobalamins 失效
    生物素化钴胺素

    公开(公告)号：US5739287A

    公开(公告)日：1998-04-14

    申请号：US406192

    申请日：1995-03-16

    Applicant: D. Scott Wilbur ,  Pradip M. Pathare ,  A. Charles Morgan, Jr.

    Inventor： D. Scott Wilbur ,  Pradip M. Pathare ,  A. Charles Morgan, Jr.

    IPC: C07H23/00 ,  A61K31/70 ,  A61K38/16 ,  C07K1/113

    CPC classification number: C07H23/00

    Abstract: A biotinylated cobalamin, formed from a vitamin B.sub.12 molecule coupled to a biotin molecule, is disclosed. In a preferred embodiment, the vitamin B.sub.12 molecule is cyanocobalamin. The biotin molecule can also be coupled to a rerouting moiety, optionally through a biotin binding protein such as avidin or streptavidin. The biotinylated cobalamin binds to a cell surface receptor, is invaginated, and once internalized affects the receptor trafficking pathway.

    Abstract translation: 公开了由与生物素分子偶联的维生素B12分子形成的生物素化钴胺素。 在优选的实施方案中，维生素B12分子是氰钴胺素。 生物素分子还可以任选地通过生物素结合蛋白例如抗生物素蛋白或链霉抗生物素蛋白偶联至重新路由部分。 生物素化的钴胺素结合细胞表面受体，是内陷的，一旦内化影响受体转运途径。

    TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS
    5.
    发明申请
    TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS 审中-公开
    转移膜抗体诱导抑制作用

    公开(公告)号：US20090274710A1

    公开(公告)日：2009-11-05

    申请号：US12421398

    申请日：2009-04-09

    Applicant: Heinz Kohler ,  Sybille Muller ,  Thomas L. Brown ,  Yunfeng Zhao ,  A. Charles Morgan, JR.

    Inventor： Heinz Kohler ,  Sybille Muller ,  Thomas L. Brown ,  Yunfeng Zhao ,  A. Charles Morgan, JR.

    IPC: A61K39/395 ,  C07K16/18

    CPC classification number: C07K14/472 ,  A61K39/00 ,  A61K2039/505 ,  C07K14/77 ,  C07K16/00 ,  C07K16/4208 ,  C07K16/4266 ,  C07K2317/74 ,  C07K2317/77 ,  C07K2319/00

    Abstract: Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis in living cells. The advantage of using trans-membrane antibodies as apoptosis inhibitors is their specific target recognition in the cell and their lower toxicity compared to conventional apoptosis inhibitors. It is shown that a MTS-transport-peptide modified monoclonal anti-caspase-3 antibody reduces actinomycin D-induced apoptosis and cleavage of spectrin in living cells. These results indicate that antibodies conjugated to a membrane transporter peptide have a therapeutic potential to inhibit apoptosis in a variety of diseases.

    Abstract translation: 细胞自杀（凋亡）与发病机制相关，例如，它是阿尔茨海默病中神经元丧失的主要原因。 Caspase-3严重参与凋亡途径。 已经使用超抗体（SAT） - 跨膜技术产生抗半胱天冬酶的抗体，以抑制活细胞凋亡。 使用跨膜抗体作为细胞凋亡抑制剂的优点是其与细胞凋亡抑制剂相比在细胞中的特异性靶标识别及其较低的毒性。 显示MTS转运肽修饰的单克隆抗半胱天冬酶-3抗体降低放线菌素D诱导的细胞凋亡和活细胞中血影蛋白的裂解。 这些结果表明，与膜转运蛋白肽缀合的抗体具有抑制多种疾病细胞凋亡的治疗潜力。

    Growth blocking agents
    9.
    发明授权
    Growth blocking agents 失效
    生长阻滞剂

    公开(公告)号：US07416728B2

    公开(公告)日：2008-08-26

    申请号：US10956735

    申请日：2004-10-01

    Applicant: A. Charles Morgan, Jr. ,  Edward V. Quadros ,  Sheldon P. Rothenberg

    Inventor： A. Charles Morgan, Jr. ,  Edward V. Quadros ,  Sheldon P. Rothenberg

    IPC: A61K39/00 ,  C07K16/00

    CPC classification number: C07K16/18 ,  A61K38/00 ,  C07K16/28

    Abstract: There is disclosed anti-receptor and growth blocking agents to the vitamin B12/transcobalamin II receptor and binding sites. The anti-receptor and growth blocking agents antagonize or modulate the vitamin B12/transcobalamin II receptor or binding sites, causing cellular depletion of vitamin B12, thus inhibiting cell division or causing apoptosis. Anti-receptor and growth blocking agents of the present invention include proteins (such as antibodies and antibody derivatives), peptides and small organic molecules. In a preferred embodiment, the anti-receptor agent is an antibody to the vitamin B12/transcobalamin II receptor.

    Abstract translation: 已经公开了对维生素B 12 / transcobalamin II受体和结合位点的抗受体和生长阻断剂。 抗受体和生长阻断剂拮抗或调节维生素B 12 / transcobalamin II受体或结合位点，引起维生素B 12细胞的细胞消耗，从而抑制细胞分裂或 引起凋亡。 本发明的抗受体和生长阻断剂包括蛋白质（例如抗体和抗体衍生物），肽和小有机分子。 在优选的实施方案中，抗受体剂是对维生素B 12 /转铁蛋白II受体的抗体。

    Methods of receptor modulation and uses therefor
    10.
    发明授权
    Methods of receptor modulation and uses therefor 失效
    受体调节方法及其用途

    公开(公告)号：US5869465A

    公开(公告)日：1999-02-09

    申请号：US406194

    申请日：1995-03-16

    Applicant: A. Charles Morgan, Jr. ,  D. Scott Wilbur

    Inventor： A. Charles Morgan, Jr. ,  D. Scott Wilbur

    IPC: C07H23/00 ,  A61K31/68 ,  C12P19/42

    CPC classification number: C07H23/00

    Abstract: Receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are utilized for the treatment and diagnosis of a variety of disorders in warm-blooded animals, including neoplastic disorders. The receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety.

    Abstract translation: 能够通过影响细胞表面受体转运途径来调节细胞表面受体的受体调节剂用于治疗和诊断温血动物（包括肿瘤性疾病）中的各种疾病。 受体调节剂由共价结合的重新路由部分和靶向部分组成。

Patent Agency Ranking